Related Experiment Video
Updated: Jul 17, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Nanocarrier-based targeting of metabolic pathways for endometrial cancer: Status and future perspectives
Yichao Wang1, Siyao Chen1, Chunling Wang2
1Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130000, China.
Abstract:
Cancer is the second-most lethal global disease, as per health reports, and is responsible for around 70% of deaths in low- and middle-income countries. Endometrial cancer is one of the emerging malignancies and has been predicted as a public health challenge for the future. Insulin resistance, obesity, and diabetes mellitus are the key metabolic factors that promote risks for the development of endometrial cancer. Various signaling pathways and associated genes are involved in the genesis of endometrial cancer, and any mutation or deletion in such related factors leads to the induction of endometrial cancer. The conventional way of drug delivery has been used for ages but is associated with poor management of cancer due to non-targeting of the endometrial cancer cells, low efficacy of the therapy, and toxicity issues as well. In this context, nanocarrier-based therapy for the management of endometrial cancer is an effective alternate choice that overcomes the problems associated with conventional therapy. In this review article, we highlighted the nanocarrier-based targeting of endometrial cancer, with a special focus on targeting various metabolic signaling pathways. Furthermore, the future perspectives of nanocarrier-based targeting of metabolic pathways in endometrial cancer were also underpinned. It is concluded that targeting metabolic signaling pathways in endometrial cancer via nanocarrier scaffolds is the future of pharmaceutical design for the significant management and treatment of endometrial cancer.
Insights
Nanocarrier-based therapy offers a promising approach for endometrial cancer treatment by targeting metabolic pathways. This innovative strategy aims to improve drug delivery, efficacy, and reduce toxicity compared to conventional methods.
Area of Science:
- Oncology
- Nanomedicine
- Metabolic Signaling
Background:
- Endometrial cancer is a growing global health concern, particularly in low- and middle-income countries.
- Metabolic factors such as insulin resistance, obesity, and diabetes mellitus are strongly linked to endometrial cancer development.
- Conventional cancer therapies face challenges including poor targeting, low efficacy, and significant toxicity.
Purpose of the Study:
- To review and highlight nanocarrier-based strategies for targeting endometrial cancer.
- To focus on the application of nanocarriers in targeting metabolic signaling pathways involved in endometrial cancer.
- To discuss future perspectives of nanocarrier-based metabolic targeting in endometrial cancer management.
Main Methods:
- Review of current literature on nanocarrier applications in oncology.
- Analysis of studies focusing on metabolic pathways in endometrial cancer.
- Synthesis of information on nanocarrier-based drug delivery systems.
Main Results:
- Nanocarrier-based therapy presents an effective alternative to conventional treatments for endometrial cancer.
- Targeting specific metabolic signaling pathways using nanocarriers can enhance therapeutic outcomes.
- Nanocarrier scaffolds show potential for improved drug delivery and reduced side effects.
Conclusions:
- Nanocarrier-based targeting of metabolic signaling pathways is a key future direction for endometrial cancer treatment.
- This approach holds significant promise for improving the management and therapeutic efficacy of endometrial cancer.
- Pharmaceutical design incorporating nanocarrier scaffolds offers a novel strategy for combating endometrial cancer.
